Gene therapies cost $2.1M to $4.25M. Insurance barriers and Medicaid gaps are reshaping access for rare disease families. A single infusion for a child with this fatal neurodegenerative disease carries a price tag higher than most people will earn in a lifetime. Hemgenix, approved in 2022 for hemophilia B, costs $3.5 million. Lyfgenia, for sickle cell disease, is $3.1 million. Casgevy, the first CRISPR-based gene therapy by Vertex, is $2.2 million. Bluebird bio developed gene therapies for beta-thalassemia (Zynteglo), sickle cell disease (Lyfgenia), and cerebral adrenoleukodystrophy (Skysona). These were not failed therapies. They worked. Patients got better. NewsGene TherapyHealthcare AccessRare Disease PolicyMarch 29, 2026 · Gene therapies offer cures for previously untreatable rare diseases, but prices reaching $4.25 million create devastating access barriers. Therapies that literally cure genetic diseases once thought incurable are now available. But for the families who need them most, these breakthroughs have become locked behind a pricing wall so high it is often impenetrable. The gap between scientific innovation and patient access has never been wider. A therapy that works exists, yet most patients cannot access it. This is not a hypothetical problem. It is the daily reality for families navigating a rare disease diagnosis.

Original title: “Gene Therapy Pricing | Rare Disease Access Barriers | Trial Friend”

As more advanced cell and gene therapies, including gene editing technologies, progress through drug development, there is increased emphasis on the importance of stakeholders, including people living with disease, caregivers, and healthcare professionals, to communicate using clear, accurate, ... As more advanced cell and gene therapies, including gene editing technologies, progress through drug development, there is increased emphasis on the importance of stakeholders, including people living with disease, caregivers, and healthcare professionals, to communicate using clear, accurate, and consistent language. The biotechnology company bluebird bio developed a suite of educational resources for patients on gene therapy aimed at an audience of “beginners to advanced learners”, including concepts and terms used to describe lentiviral gene therapy for beta-thalassemia and sickle cell disease [37]. Topics include descriptions and examples of genetic diseases, gene therapy approaches and clinical trials, a comprehensive glossary defining terms used in their resources, and step-by-step explanations of the gene therapy process [37]. The Thalassaemia International Federation has also produced a comprehe Similarly, gene editing terms are described in the GenePossibilities educational materials developed by Vertex Pharmaceuticals for patients and HCPs, hosted on separate dedicated sites [40, 41]; notably, the patient glossary includes phonetic pronunciation. It is interesting that, despite the availability of lexicons for diseases such as hemophilia, beta-thalassemia, and sickle cell disease, patient interest and uptake of gene therapies have been slow [42]. The lexicon has been beta-tested with two large hemophilia patient advocacy groups, the National Bleeding Disorders Foundation in the USA and the European Haemophilia Consortium. The collaborative, community-based approach used in the development of the hemophilia lexicon makes it particularly well-suited for further testing, as the initial participants represent a cross-section of key stakeholders involved in hemophilia gene editing therapy.

Original title: “Building a gene editing lexicon: a model for rare and inherited disorders | Gene Therapy”